GlassScriptPhysician profile
Jorge I Contreras
NPI 1033315411
$8,601.86
in general payments reported to CMS, 2019-2025
20 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $120 · 2021: $2,639 · 2022: $2,233 · 2023: $361 · 2024: $1,031 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,651 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,650.94 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,490.81 | 2021-2022 | |
| Medical Device Business Services, INC. | $1,500.30 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $959.36 | 2021-2025 | Dupixent |
| Genzyme Corporation | $766.20 | 2022-2025 | |
| Inspire Medical Systems, INC. | $708.82 | 2019 | |
| Stryker Corporation | $502.99 | 2019-2025 | Scopis Ent, Clarifix Cryotherapy Device, N/A |
| Glaxosmithkline, LLC. | $294.52 | 2021-2025 | Nucala |
| Integra Lifesciences Corporation | $268.84 | 2024 | Inspira Air, Acclarent Aera, Trudi Probe |
| Acclarent, INC | $250.84 | 2022 | |
| Aerin Medical INC. | $247.49 | 2023-2025 | |
| Intuitive Surgical, INC. | $176.11 | 2022 | |
| Medtronic, INC. | $129.71 | 2022-2025 | Propel |
| Optinose US, INC. | $124.73 | 2019-2020 | |
| Karl Storz Endoscopy-America | $50.23 | 2020 | |
| Novartis Pharmaceuticals Corporation | $31.31 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $23.64 | 2025 | Exparel |
| Paratek Pharmaceuticals, INC. | $22.01 | 2025 | Xhance |
| Sanofi-Aventis U.S. LLC | $20.41 | 2020 | |
| Allergan, INC. | $17.77 | 2019 | |
| Davol INC. | $15.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Contreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.